Clinical trials: Endometrial Neoplasms
Endometrial Neoplasms, DNA Methylation
Cervical Cytology DNA Methylation for Endometrial Lesion Screening and Follow-up
The goal of this observational study is to evaluate the accuracy of a novel molecular test for screening and monitoring endometrial lesions in women at medium-to-high risk for endometrial cancer.
- Conditions
- Endometrial Neoplasms, DNA Methylation, Cervical Smears, Early Detection of Cancer
- Trial name
- EndoMethy-V (NCT07298707)
- Volunteers
- 3,500 people
- Sponsor
- Peking Union Medical College Hospital
Atypical Endometrial Hyperplasia, Endometrial Carcinoma
Megestrol Acetate With or Without Pterostilbene in Treating Patients With Endometrial Cancer Undergoing Hysterectomy
This phase II trial studies how well megestrol acetate with or without pterostilbene works in treating patients with endometrial cancer undergoing hysterectomy.
- Trial name
- NCT03671811
- Testing
- Megestrol Acetate, Pterostilbene
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- City of Hope Medical Center
Endometrial Cancer
A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer.
The purpose of this study is to investigate the efficacy and safety of the lifileucel regimen in participants with previously treated endometrial cancer.
- Trial name
- NCT06481592
- Testing
- Lifileucel
- Where
- 12 sites in United States
- Volunteers
- 60 people
- Sponsor
- Iovance Biotherapeutics, Inc.
Colorectal Cancer, Cholangiocarcinoma
A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors
This is an open-label, Phase 1/2 study to determine the safety, tolerability, and efficacy of APL-5125 for the treatment of selected locally advanced or metastatic solid tumors with particular focus on Colorectal carcinoma (CRC).
- Conditions
- Colorectal Cancer, Cholangiocarcinoma, Appendiceal Adenocarcinoma, Pancreatic Adenocarcinoma
- Trial name
- NCT06399757
- Testing
- APL-5125
- Where
- 9 sites in United States
- Volunteers
- 27 people
- Sponsor
- Apollo Therapeutics Ltd
Endometrial Cancer
Evaluation of Carboplatin/Paclitaxel With and Without Trastuzumab (Herceptin) in Uterine Serous Cancer
The primary objective of this study is to estimate whether the addition of trastuzumab to paclitaxel and carboplatin chemotherapy improves progression free survival when compared to paclitaxel and carboplatin alone in Uterine…
- Trial name
- NCT01367002
- Testing
- Carboplatin/Paclitaxel, Trastuzumab
- Where
- 20 sites in United States
- Volunteers
- 61 people
- Sponsor
- Yale University
Circulating Tumor DNA, Endometrial Cancer
Reliability and Interest of Circulating Tumor DNA in Endometrial Cancers.
The recent histo-prognostic molecular discoveries of the TCGA (The Cancer Genome Atlas) have shed new light on the classification of endometrial carcinomas.
- Trial name
- NCT04456972
- Testing
- One arm only
- Where
- France
- Volunteers
- 44 people
- Sponsor
- Poitiers University Hospital
Endometrial Cancer
Adaptive Daily MR-Guided Adjuvant Pelvic Therapy-Endometrial Cancer
To evaluate the safety, tolerability, and preliminary efficacy of moderately hypofractionated (15-fraction) MR-guided adaptive pelvic IMRT in patients with endometrial cancer.
- Trial name
- ADAPT-EC (NCT07643012)
- Testing
- MR-guided adaptive pelvic intensity-modulated radiation therapy (IMRT)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Rutgers, The State University of New Jersey
Cervical Cancer, Endometrial Cancer
Standard Versus Intensity-Modulated Pelvic Radiation Therapy in Treating Patients With Endometrial or Cervical Cancer
RATIONALE: Radiation therapy uses high-energy x-rays and other types of radiation to kill tumor cells. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause…
- Conditions
- Cervical Cancer, Endometrial Cancer, Gastrointestinal Complications, Perioperative/Postoperative Complications
- Trial name
- NCT01672892
- Testing
- Standard radiation therapy, intensity-modulated radiation therapy
- Where
- 137 sites in United States, Canada and 2 more
- Volunteers
- 289 people
- Sponsor
- Radiation Therapy Oncology Group
Endometrial Cancer
Single Agent ONC201 in Recurrent or Metastatic Endometrial Cancer
ONC201 is a small molecule which selectively targets the G protein-coupled receptor DRD2. Downstream of target engagement, ONC201 activates the integrated stress response (ISR) in tumor cell leading to inactivation of Akt and…
- Trial name
- NCT03099499
- Testing
- ONC201
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Fox Chase Cancer Center
Quality of Life, Endometrial Cancer
Quality of Life After Robotic Surgery for Endometrial Cancer
The purpose of this study is to investigate how robotic assisted laparoscopic surgery affects the quality of life of women who are treated with primary surgery for endometrial cancer.
- Conditions
- Quality of Life, Endometrial Cancer, Surgery--Complications, Gynecologic Cancer
- Trial name
- QoL (NCT04281043)
- Where
- Sweden
- Volunteers
- 64 people
- Sponsor
- Sahlgrenska University Hospital
Endometrial Cancer
An Endometrial Cancer Study for Women With Recurrent or Persistent Endometrial Cancer
This is an open-label, multi-center, single-arm, two-period Phase 2 study. The study will investigate the efficacy of Sodium Cridanimod in conjunction with progestin therapy in a population of subjects with recurrent or…
- Trial name
- NCT03077698
- Testing
- Sodium Cridanimod, progestin therapy
- Where
- 25 sites in United States
- Volunteers
- 25 people
- Sponsor
- Xenetic Biosciences, Inc.
Endometrial Cancer
Sentinel Lymph Node Mapping With Different Injection Sites of ICG in Endometrium Cancer
The primary goal of this prospective study is to define the efficacy of the sentinel lymph node biopsy (SLNB) procedure by comparing different method performed in patients with endometrial cancer.
- Trial name
- SLN-EC-01 (NCT06656949)
- Testing
- injecting indocyanine green (ICG) dye Intraoperative
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Qilu Hospital of Shandong University
Solid Tumor
A Clinical Study of the Safety and Effectiveness of an Investigational Cell Therapy Given With and Without an Investigational RNA-based Vaccine in Patients With Organ Tumors
This is a Phase I, FIH, open-label, multi-site, dose escalation trial with expansion cohorts to evaluate safety and preliminary efficacy of claudin 6 (CLDN6) chimeric antigen receptor T cells (CAR-T) with or without CLDN6…
- Trial name
- NCT04503278
- Testing
- CLDN6 CAR-T, CLDN6 uRNA-LPX/CLDN6 modRNA-LPX
- Where
- 12 sites in Australia, Germany and 2 more
- Volunteers
- 214 people
- Sponsor
- BioNTech Cell & Gene Therapies GmbH
Endometrial Hyperplasia and Endometrial Cancers
Role of Senescence in the Development of Endometrial Cancer
Several molecular studies showed chromosomal alterations in patients with endometrial cancer, with gains in 1q, 19p, 19q, 8q, 10q and 10p and loss of 4q, 16q and 18q.
- Trial name
- NCT03338985
- Testing
- Genetic analysis
- Where
- France
- Volunteers
- 140 people
- Sponsor
- CHU de Reims
Endometrial Cancer
Letrozole and RAD001 With Advanced or Recurrent Endometrial Cancer
The goal of this clinical research study is to learn if the combination of RAD001 (everolimus) and Femara (letrozole) can help to control recurrent or progressive endometrial cancer.
- Trial name
- NCT01068249
- Testing
- Letrozole, RAD001 (Everolimus)
- Where
- 2 sites in United States
- Volunteers
- 42 people
- Sponsor
- M.D. Anderson Cancer Center
Advanced Solid Tumors, Breast Cancer Recurrent
First-in-Human Study of ATX-559, an Oral Inhibitor of DHX9, in Patients With Advanced or Metastatic Solid Tumors, and Molecularly Defined Cancers
The goal of this study is to identify a safe and tolerated dose of the orally administered DHX9 inhibitor ATX-559. In addition, this study will evaluate the pharmacokinetics, pharmacodynamics and preliminary antitumor activity of…
- Conditions
- Advanced Solid Tumors, Breast Cancer Recurrent, Colorectal Cancer Metastatic, Colon Cancer
- Trial name
- NCT06625515
- Testing
- ATX-559
- Where
- 5 sites in United States
- Volunteers
- 17 people
- Sponsor
- Accent Therapeutics
Metastatic Cancer, Cancer
A Study of BIND-014 Given to Patients With Advanced or Metastatic Cancer
The goal of this Phase 1 clinical research study is to find the highest safe dose of BIND-014 that can be given in the treatment of patients with advanced or metastatic cancer.
- Conditions
- Metastatic Cancer, Cancer, Solid Tumors
- Trial name
- NCT01300533
- Testing
- BIND-014
- Where
- 6 sites in United States
- Volunteers
- 58 people
- Sponsor
- BIND Therapeutics
Endometrial Neoplasms, Endometrial Cancer
Symbiotic-GYN-18: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Advanced or Recurrent MMR-proficient Endometrial Cancer
This study is being conducted to assess whether the study medicine PF 08634404, given in combination with chemotherapy, improves outcomes compared with another medicine called pembrolizumab plus chemotherapy.
- Trial name
- NCT07578649
- Testing
- PF-08634404, Pembrolizumab, Standard of Care Chemotherapy
- Where
- 43 sites in United States, Australia and 2 more
- Volunteers
- 600 people
- Sponsor
- Pfizer
Endometrial Neoplasms
Lenvatinib in Second Line Endometrial Carcinoma
The primary objective of this multicenter, randomized phase II trial is to assess the efficacy, as measured by progression-free survival (PFS), of lenvatinib compared to doxorubicin in advanced or recurrent endometrial cancer.
- Trial name
- NCT03005015
- Testing
- Lenvatinib, Doxorubicin
- Where
- Switzerland
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Advanced Solid Malignancy, Safety and Tolerability
Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules
This study is designed to investigate the safety and tolerability of a new drug, AZD5363, in patients with advanced cancer - and to identify a dose and schedule that can be used in the future.
- Conditions
- Advanced Solid Malignancy, Safety and Tolerability, Pharmacokinetics, Pharmacodynamics
- Trial name
- NCT01226316
- Testing
- AZD5363
- Where
- 34 sites in United States, Canada and 8 more
- Volunteers
- 285 people
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.